Repeat Dosing of Psilocybin in Migraine Headache

Status Completed

Clinical Trial Summary

In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.

Clinical Trial Description

Migraine headache is a common medical condition and a top cause of disability worldwide. Treatment options for migraine headache are many and varied, though an approximated 10% of migraineurs is refractory to medication and thus, there is a need to develop alternative treatments. There is anecdotal evidence supporting lasting therapeutic effects after limited dosing of psilocybin and related compounds in headache disorders. The cause of this unique effect remains unknown, though the drug class has demonstrable anti-inflammatory activity, a biological process relevant to migraine and other headache disorders. In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured. The results from this study will serve in the development of larger investigations seeking to understand the effects of psilocybin and related compounds in headache disorders. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04218539
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Phase 1
Start date	August 10, 2021
Completion date	November 5, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Not yet recruiting	`NCT05943457` - Vitamin K2 Supplementation in Adult Episodic Migraine	N/A
Completed	`NCT01211145` - Zomig - Treatment of Acute Migraine Headache in Adolescents	Phase 4
Completed	`NCT00530517` - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack	Phase 2
Completed	`NCT00898677` - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)	Phase 3
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Completed	`NCT03971071` - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache	Phase 4
Withdrawn	`NCT02706015` - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks	Phase 3
Completed	`NCT02518464` - Ticagrelor Therapy for RefrACTORy Migraine Study	Phase 4
Terminated	`NCT02375789` - Intranasal Cooling for Symptomatic Relief of Migraine	N/A
Terminated	`NCT00391755` - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches	Phase 4
Completed	`NCT03401346` - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults	Phase 1
Completed	`NCT05085483` - Ketone for Migraine Prevention	N/A
Completed	`NCT01604785` - Low-dose Propofol for Pediatric Migraine	Phase 2/Phase 3
Terminated	`NCT00804973` - Study in Participants With Acute Migraines Headaches	Phase 2
Completed	`NCT03341689` - Psilocybin for the Treatment of Migraine Headache	Phase 1
Completed	`NCT01630044` - Neurostimulation Device for Treatment of Migraine Headache	N/A
Active, not recruiting	`NCT00285402` - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine	Phase 2
Completed	`NCT00203255` - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache	N/A
Recruiting	`NCT06046508` - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)